<DOC>
	<DOCNO>NCT01219699</DOCNO>
	<brief_summary>This first-in-man trial , BYL719 administer adult patient advance solid tumor , whose tumor alteration PIK3CA gene whose disease progress despite standard therapy standard therapy exist . A combination BYL719 fulvestrant also investigate post-menopausal patient locally advance metastatic breast cancer whose tumor alteration PIK3CA gene . The single agent MTD dose expansion cohort fulvestrant combination MTD dose expansion cohort also include ER+/HER2- breast cancer patient whose tumor wild type PIK3CA gene</brief_summary>
	<brief_title>A Study BYL719 Adult Patients With Advanced Solid Malignancies , Whose Tumors Have Alteration PIK3CA Gene</brief_title>
	<detailed_description />
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Patients histologicallyconfirmed , advance unresectable solid tumor progress within three month screening/baseline visit Only patient confirm PIK3CA status ( wild type , mutation amplification ) allow screen ( patient participate combination arm must eligible treatment fulvestrant ) Availability representative formalin fix paraffin embed tumor tissue sample At least one measurable nonmeasurable lesion Age ≥ 18 year World Health Organization ( WHO ) Performance Status ≤ 2 Good organ ( hepatic , kidney , BM ) function screening/baseline visit Brain metastasis unless treat free signs/symptoms attributable brain metastasis absence corticosteroid therapy ( antiepileptic therapy allow ) . Prior treatment PI3K , AKT mTOR inhibitor failure benefit Patient peripheral neuropathy NCICTC Grade ≥ 3 Patient diarrhea NCICTC Grade ≥ 2 Patient acute chronic pancreatitis Impaired cardiac function clinically significant cardiac disease incl . unstable angina pectoris ≤ 3 month prior start study drug Acute Myocardial Infarction ( AMI ) ≤ 3 month prior start study drug . Patients clinically manifest diabetes mellitus , history gestational diabetes mellitus document steroidinduced diabetes mellitus Women pregnant breast feeding adult reproductive potential employ effective method birth control Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>advanced solid tumor</keyword>
	<keyword>mutation</keyword>
	<keyword>amplification</keyword>
	<keyword>wild type</keyword>
	<keyword>PIK3CA gene</keyword>
	<keyword>dose-escalation</keyword>
	<keyword>estrogen receptor positive breast cancer</keyword>
</DOC>